JPMorgan maintains UBS stock Overweight rating and CHF37 target

Published 02/06/2025, 08:14
JPMorgan maintains UBS stock Overweight rating and CHF37 target

On Monday, JPMorgan reiterated its Overweight rating and CHF37.00 price target on UBS Group AG (UBSG:SW) (NYSE:UBS). The firm’s analysis anticipates significant regulatory developments that could impact the banking giant’s capital requirements and shareholder returns.

The Swiss Federal Council is expected to initiate a public consultation on June 6 concerning banking stability reforms. These proposed measures are particularly focused on the capital treatment of foreign participations, which is slated to be regulated at the legislative level. For UBS Group, this could mean an increase in capital run-rate requirements.

According to JPMorgan, if the scenario of 100% coverage of foreign participations through going concern capital is adopted, UBS Group might require an additional $20 billion in capital at the Parent Bank level. However, this figure could potentially decrease to $12.8 billion as capital is repatriated over time, mainly from Credit Suisse International and partly from the U.S. Intermediate Holding Company (IHC), pending regulatory approvals.

This adjustment in capital could lower JPMorgan’s 2027 estimated return on CET1 capital (RoCET1) for UBS from 16.1% to 14.3%. This estimate is based on a CET1 ratio of 16.6% for 2027, with an extreme scenario including the elimination of $12 billion in share buybacks from the 2026-27 estimates to fill the capital shortfall. JPMorgan has indicated that it will revisit its buyback assumptions following the release of the proposals.

The outcome of these regulatory changes is also expected to influence the shareholder payout potential of UBS Group in the short term. The use of upstreamed capital from UBS AG to UBS Group AG standalone will be divided between resolving the double leverage issue and distributing payouts to shareholders, with the level of equity double leverage UBS decides to operate with being a critical factor.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.